TABLE 2.

Variant CJD inoculation into glycosylation-deficient mice at first and second^a passages

Mouse line	Inoculum	Incubation timeb (days) ± SEM (range)	Clinical disease (no. positive/total no.)	TSE vac and/or PrP depositionc	Survival time (days) of mice with TSE vac and/or PrPd
G1	vCJD		0/17	0/17
G2	vCJD	536 ± 16 (510–600)	8/18	14/18	611 ± 29 (505–708)
G3	vCJD		0/19	0/19
Wt	vCJD	477 ± 15 (380–616)	21/40	36/40	483 ± 18 (310–616)
G2	G2vCJDa	283 ± 3	10/11	11/11
Wt	G2vCJDa	192 ± 2	12/12	12/12
G2	G2vCJDb	315 ± 3	11/12	12/12
Wt	G2vCJDb	193 ± 3	12/12	12/12
G2	WtvCJD	334 ± 6	11/13	13/13
Wt	WtvCJD	156 ± 1	12/12	12/12

^aBrain material from two vCJD-inoculated G2 mice and one vCJD inoculated wild-type mouse with pathological evidence of disease were further passaged into G2 and wild-type mice.

^bIncubation time for mice with clinical signs and evidence of TSE vacuolation. Studies were maintained to ∼700 dpi for mice with no clinical signs of TSE disease.

^cTSE vacuolation and/or PrP deposition were used as evidence of transmission for primary passage due to low numbers of mice with clinical signs and vacuolation present. Limited confirmatory immunohistochemistry for PrP deposition was carried out in the second passage due to high numbers of mice with clinical signs and vacuolation present.

^dSurvival time of mice with no clinical signs and evidence of TSE vacuolation and/or PrP deposition.